Abstract
Coronavirus disease (COVID-19) is a contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This case report presents a patient who had difficulty eradicating the corona virus due to being treated with Rituximab, which depletes B lymphocyte cells and therefore disables the production of neutralizing antibodies. The combined use of external anti-viral agents like convalescent plasma, IVIG and Remdesivir successfully helped the patient’s immune system to eradicate the virus without B-cell population recovery. In vitro studies showed that convalescent plasma is the main agent that helped in eradicating the virus.
| Original language | English |
|---|---|
| Article number | 8902 |
| Journal | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
| Volume | 22 |
| Issue number | 16 |
| DOIs | |
| State | Published - 18 Aug 2021 |
Bibliographical note
Publisher Copyright:© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Keywords
- Immunocompromised
- Pneumonia
- SARS-COV-2
- T lymphocytes
Fingerprint
Dive into the research topics of 'Clearance of the SARS-CoV-2 virus in an immunocompromised patient mediated by convalescent plasma without B-cell recovery'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver